美通社

2024-10-21 13:57

Great Bay Bio Intelligent Drug Development Ecosystem Officially Launched

HONG KONG, Oct. 20, 2024 /PRNewswire/ -- On October 18th, the new product launch event hosted by Great Bay Bio (hereinafter referred to as "GBB") was successfully held in Suzhou, where industry players gathered to celebrate the feast of technological innovation. At the event, GBB announced the official launch of the Intelligent Drug Development Ecosystem. The Intelligent Drug Development Ecosystem empowers the entire process of drug discovery and bioprocess development, from drug discovery, molecular sequence generation and optimization, to cell line development, to culture media development and optimization, etc., giving revolutionary changes to biopharmaceutical development, helping customers develop products faster and better.

Mr. Kingsley Leung, co-founder and chairman of GBB, said: "I am very happy to discuss the new future of the industry with many colleagues in biopharmaceuticals in Suzhou. We always believe that technology's power can change the biopharmaceutical development pattern. Through the Intelligent Drug Development Ecosystem, we have brought revolutionary changes to biopharmaceutical development and solved the problems of long drug development cycles, high costs, and low success rates that have long plagued the industry. In the future, Great Bay Bio will adhere to technological innovation and work with global partners to further promote the transformation and development of the biopharmaceutical industry, so that patients around the world can enjoy the benefits brought by scientific and technological progress."

Intelligent Drug Development Ecosystem
Intelligent Drug Development Ecosystem

Dr. Michael Chen, co-founder and CEO of Great Bay Bio, remarked, "The Intelligent Drug Development Ecosystem has evolved alongside the establishment of various intelligent technology platforms at Great Bay Bio and the successful launch of multiple products, gradually progressing from its initial concept to a fully mature system. The Intelligent Drug Development Ecosystem significantly shortens drug development timelines and increases product yield."

In the drug molecule discovery and optimization part, the AlfaDAX platform pioneeringly synchronizes optimization across the three dimensions of humanization, affinity, and druggability, achieving an approximately 90% accuracy in druggability prediction. Customers comprehensively assess the potential of protein candidates to become developable, safe, and effective drugs through protein structure prediction, affinity/hydrophobic group analysis, positive/negative charge aggregation, immunogenicity (humanization), molecular docking, and affinity analysis. Before the candidate protein molecule enters the CMC stage, the AlfaDAX platform helps customers quickly screen and modify the candidate molecule, reduce the cost of trial and error, and accelerate the process of new drug development.

In the cell line development part, the AlfaCell platform combines AI technology with site-specific integration technology to quickly analyze and precisely locate the target product gene, inserting it into the stable and high-yield "hot spot", eliminating the random and blind selection process in cell line development. The AlfaCell platform can obtain stable and high-yield monoclonal cell lines within 1.5 months, and the customer products that have been declared for IND have reached 15g/L, and the AlfaCell platform is particularly outstanding in solving the problem of bispecific antibody development, with nanobody products reaching 13.1g/L and quadruple bispecific antibody reaching 8.3g/L.

In the cell culture media development and optimization part, the AlfaMedX culture media have good universality, and the culture results are comparable or better than those of commercial media. The AlfaOPA platform uses AI technology to deeply analyze the supernatant data in the cell culture process, calculate the influencing parameters of amino acids, vitamins, metal elements and other components, and intelligently optimize the added components and amounts required for cell culture media to further improve product yield. 

Moreover, the intelligent technology platforms in the ecosystem can help customers quickly and effectively screen drug targets, discover new products, and accelerate the rapid entry of products into clinical stages.

AlfaCell - Transient

AlfaCell - Transient Transfection Kit utilizes site-specific integration technology, which can be used both for transient protein sample preparation and for stable cell line development for IND filing. Products produced through transient transfection using AlfaCell cell lines are consistent in quality with those produced during later-stage manufacturing, significantly reducing development risks. 

AlfaMedX Culture Media

The protein expression of AlfaMedX culture media is comparable to or better than commercial media, with up to a 200% increase. The media demonstrate excellent versatility, making them suitable for cultivating cell lines for various products.

AlfaNulla Precision Weighing System

The AlfaNulla Precision Weighing System is another intelligent and automated product of GBB. It completely eliminates errors caused by improper manual operation, making the media weighing process intelligent and efficient. The system significantly shortens the raw material weighing time, and the final weighing results are 100% accurate, effectively reducing labor and material costs.

source: Great Bay Bio Limited

【立即投票】今個農曆新年你會如何度過? ► 立即投票

人氣文章
最近7天
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
高息定存 | 富邦推快閃定存優惠3個月3.9厘,華僑188日3.68厘
3
高息定存 | 工銀亞洲推3個月5厘息搶新客,招商永隆推快閃優惠
4
【FOCUS】零售寒冬襲京滬港,逆市奇葩值借鏡
5
港股 | 蕭猷華:恒指料退守至18600點,宜逢低吸納
6
內銀股 | 人行再提擇機減息降準,內銀獲中金唱好,應該點部署?
7
神州經脈 | 換手機可獲政府補貼,政策利率將降,滬指周挫逾5%
8
大國博弈 | 【FOCUS】騰訊商湯寧德重挫,CMC清單劍指軍民融合
9
新股掛牌 | 布魯可首日掛牌升41%,每手賺7395元
10
加州山火 | 【FOCUS】洛杉磯烈火焚城,天災背後藏人禍
11
高息定存 | 一周高息合集,恒生1個月定存4厘,工銀亞洲3個月最高5厘
12
高息定存 | 渣打特選客6個月3.48厘,建行亞洲推1個月6.18厘高息吸客
13
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
14
一本萬利 | 2025年的五個「勿」(有片)
15
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
16
互聯支付 | 黃俊碩:轉數快與IBPS互聯支付所產生的發展契機
17
高息定存 | 一周高息合集,銀行高息吸客,低門檻10萬享6.18厘,3個月最高5厘
18
港股 | 蕭猷華:恒指春節前目標21500點
19
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
20
神州經脈 | 基金賣股票據報受限,滬指連跌四日,人行穩匯率
21
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
22
易經看世界 | 從乙巳年立春八字看香港前景:哪行業當旺?哪行業運滯?(有片)
23
習近平應約與特朗普通電話,特:冀盡快與習見面
24
財政預算案2025 | 羅兵咸料本財年財赤948億,財政儲備降至紀錄新低
25
加州山火 | 美國洛杉磯大火失控,被迫撤離人數增至18萬
26
【FOCUS】去年貿易順差破紀錄,中國擴消費增緊迫感
27
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
28
賣地計劃 | 政府今季推一幅東涌住宅地涉745伙,全年供應不達標
29
加州山火造成超500億美元損失,大量房主未買保險
30
【FOCUS】侵侵就職倒數一周,美元及油價劇本臨揭盅
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

秋天養生食療

山今養生智慧

輕鬆護老